Hilfenhaus J, Christ H, Köhler R, Moser H, Kirchner H, Levy H B
Med Microbiol Immunol. 1981;169(4):225-35. doi: 10.1007/BF02125522.
The efficacy of a herpes simplex virus type 1 (HSV-1) envelope antigen (EAG) preparation against HSV infection was studied in T cell competent and T cell deficient mice. Immuno-competent mice were successfully protected against herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2) infection when immunized 2 weeks prior to this infection with a heat-inactivated whole virus preparation or a HSV-1 envelope antigen (HSV-1 EAG) preparation. Since HSV-1 EAG was considerably less effective than the whole virus preparation, a poly.riboinosinic-poly.ribocytidylic acid complex with poly-L-lysine and carboxymethylcellulose (PICLC) was used as adjuvant. Immunization with HSV-1 EAG plus PICLC resulted in a pronounced increase of this protection rate as compared with that obtained after immunization solely with HSV-1 EAG. PICLC alone, however, offered no protection when given 2 weeks before challenge. In T cell deficient nu/nu mice no protection was achieved with HSV-1 EAG while their T cell competent, heterozygous littermates were protected. From these results it may be concluded that T cell competence is a prerequisite for establishing a protective immunity against HSV infection after immunization with HSV-1 EAG.
在有T细胞活性和无T细胞活性的小鼠中研究了1型单纯疱疹病毒（HSV-1）包膜抗原（EAG）制剂对HSV感染的疗效。在用热灭活的全病毒制剂或HSV-1包膜抗原（HSV-1 EAG）制剂在感染前2周进行免疫时，免疫活性小鼠成功地受到了1型单纯疱疹病毒（HSV-1）或2型单纯疱疹病毒（HSV-2）感染的保护。由于HSV-1 EAG的效果远不如全病毒制剂，因此使用了与聚-L-赖氨酸和羧甲基纤维素（PICLC）形成的聚肌苷酸-聚胞苷酸复合物作为佐剂。与仅用HSV-1 EAG免疫后获得的保护率相比，用HSV-1 EAG加PICLC免疫导致该保护率显著提高。然而，单独给予PICLC在攻击前2周时没有提供保护作用。在无T细胞活性的裸鼠中，HSV-1 EAG没有提供保护作用，而它们有T细胞活性的杂合子同窝小鼠则受到了保护。从这些结果可以得出结论，T细胞活性是在用HSV-1 EAG免疫后建立针对HSV感染的保护性免疫的先决条件。
